| Year |
Citation |
Score |
| 2023 |
Khushalani NI, Harrington KJ, Melcher A, Bommareddy PK, Zamarin D. Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment. Molecular Therapy Oncolytics. 31: 100729. PMID 37841530 DOI: 10.1016/j.omto.2023.100729 |
0.338 |
|
| 2020 |
Burman B, Pesci G, Zamarin D. Newcastle Disease Virus at the Forefront of Cancer Immunotherapy. Cancers. 12. PMID 33260685 DOI: 10.3390/cancers12123552 |
0.367 |
|
| 2020 |
Campesato LF, Budhu S, Tchaicha J, Weng CH, Gigoux M, Cohen IJ, Redmond D, Mangarin L, Pourpe S, Liu C, Zappasodi R, Zamarin D, Cavanaugh J, Castro AC, Manfredi MG, et al. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine. Nature Communications. 11: 4011. PMID 32782249 DOI: 10.1038/S41467-020-17750-Z |
0.371 |
|
| 2020 |
Raghavan S, Snyder CS, Wang A, McLean K, Zamarin D, Buckanovich RJ, Mehta G. Carcinoma-Associated Mesenchymal Stem Cells Promote Chemoresistance in Ovarian Cancer Stem Cells via PDGF Signaling. Cancers. 12. PMID 32726910 DOI: 10.3390/Cancers12082063 |
0.318 |
|
| 2020 |
Zamarin D, Hamid O, Nayak-Kapoor A, Sahebjam S, Sznol M, Collaku A, Fox FE, Marshall MA, Hong DS. Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: a Phase I Study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 32586937 DOI: 10.1158/1078-0432.Ccr-20-0328 |
0.317 |
|
| 2020 |
Boland JL, Zhou Q, Iasonos AE, O'Cearbhaill RE, Konner J, Callahan M, Friedman C, Aghajanian C, Sabbatini P, Zamarin D, Cadoo KA. Utility of serum CA-125 monitoring in patients with ovarian cancer undergoing immune checkpoint inhibitor therapy. Gynecologic Oncology. PMID 32507515 DOI: 10.1016/J.Ygyno.2020.04.710 |
0.322 |
|
| 2020 |
Zamarin D, Walderich S, Holland A, Zhou Q, Iasonos AE, Torrisi JM, Merghoub T, Chesebrough LF, Mcdonnell AS, Gallagher JM, Li Y, Hollmann TJ, Grisham RN, Erskine CL, Block MS, et al. Safety, immunogenicity, and clinical efficacy of durvalumab in combination with folate receptor alpha vaccine TPIV200 in patients with advanced ovarian cancer: a phase II trial. Journal For Immunotherapy of Cancer. 8. PMID 32503949 DOI: 10.1136/Jitc-2020-000829 |
0.338 |
|
| 2020 |
Jiménez-Sánchez A, Cybulska P, Mager KL, Koplev S, Cast O, Couturier DL, Memon D, Selenica P, Nikolovski I, Mazaheri Y, Bykov Y, Geyer FC, Macintyre G, Gavarró LM, Drews RM, ... ... Zamarin D, et al. Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. Nature Genetics. PMID 32483290 DOI: 10.1038/S41588-020-0630-5 |
0.403 |
|
| 2020 |
Nguyen B, Mota JM, Nandakumar S, Stopsack KH, Weg E, Rathkopf D, Morris MJ, Scher HI, Kantoff PW, Gopalan A, Zamarin D, Solit DB, Schultz N, Abida W. Pan-cancer Analysis of CDK12 Alterations Identifies a Subset of Prostate Cancers with Distinct Genomic and Clinical Characteristics. European Urology. PMID 32317181 DOI: 10.1016/J.Eururo.2020.03.024 |
0.317 |
|
| 2020 |
Zamarin D, Burger RA, Sill MW, Powell DJ, Lankes HA, Feldman MD, Zivanovic O, Gunderson C, Ko E, Mathews C, Sharma S, Hagemann AR, Khleif S, Aghajanian C. Randomized Phase II Trial of Nivolumab Versus Nivolumab and Ipilimumab for Recurrent or Persistent Ovarian Cancer: An NRG Oncology Study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO1902059. PMID 32275468 DOI: 10.1200/Jco.19.02059 |
0.31 |
|
| 2020 |
Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, ... ... Zamarin D, et al. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. Journal For Immunotherapy of Cancer. 8. PMID 32209603 DOI: 10.1136/Jitc-2019-000337 |
0.302 |
|
| 2020 |
Bykov Y, Kim SH, Zamarin D. Preparation of single cells from tumors for single-cell RNA sequencing. Methods in Enzymology. 632: 295-308. PMID 32000902 DOI: 10.1016/Bs.Mie.2019.05.057 |
0.342 |
|
| 2020 |
Kim SH, Da Cruz Paula A, Basili T, Dopeso H, Bi R, Pareja F, da Silva EM, Gularte-Mérida R, Sun Z, Fujisawa S, Smith CG, Ferrando L, Martins Sebastião AP, Bykov Y, Li A, ... ... Zamarin D, et al. Identification of recurrent FHL2-GLI2 oncogenic fusion in sclerosing stromal tumors of the ovary. Nature Communications. 11: 44. PMID 31896750 DOI: 10.1038/S41467-019-13806-X |
0.347 |
|
| 2020 |
Vijayakumar G, Zamarin D. Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation. Methods in Molecular Biology (Clifton, N.J.). 2058: 133-154. PMID 31486036 DOI: 10.1007/978-1-4939-9794-7_9 |
0.739 |
|
| 2020 |
Miller K, Filippova OT, Hayes SA, Abu-Rustum N, Aghajanian C, Broach V, Ellenson LH, Jewell EL, Kyi C, Lakhman Y, Mueller JJ, O'Cearbhaill RE, Park KJ, Sonoda Y, Zamarin D, et al. Pattern of disease in recurrent cervical cancer associated with response to pembrolizumab. Journal of Clinical Oncology. 38: e18006-e18006. DOI: 10.1200/Jco.2020.38.15_Suppl.E18006 |
0.332 |
|
| 2020 |
Minev B, Santidrian AF, Minev I, Nguyen D, Zamarin D, Marincola F, Draganov DD. Enhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms. Journal of Clinical Oncology. 38: e15271-e15271. DOI: 10.1200/Jco.2020.38.15_Suppl.E15271 |
0.446 |
|
| 2020 |
Zamarin D, Odunsi K, Slomovitz BM, Duska LR, Nemunaitis JJ, Reilley M, Bykov Y, Holland A, Hubbard-Lucey VM, Shohara L, Schwarzenberger P, Ricciardi T, Macri MJ, Ryan A, Jaderberg ME, et al. Phase I/II study to evaluate systemic durvalumab + intraperitoneal (IP) ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC): Interim phase I clinical and translational results. Journal of Clinical Oncology. 38: 3017-3017. DOI: 10.1200/Jco.2020.38.15_Suppl.3017 |
0.384 |
|
| 2020 |
Campesato LF, Budhu S, Gigoux M, Tchaicha J, Pourpe S, Liu C, Zamarin D, Manfredi MG, McGovern K, Wolchok JD, Merghoub T. Abstract PR05: Blockade of AHR activation by IDO/TDO-derived kynurenine restricts cancer immune suppression Cancer Immunology Research. 8. DOI: 10.1158/2326-6074.Tumimm18-Pr05 |
0.375 |
|
| 2020 |
Zamarin D. Abstract IA19: Immunotherapy in ovarian cancer: Challenges and novel opportunities Clinical Cancer Research. 26. DOI: 10.1158/1557-3265.Ovca19-Ia19 |
0.439 |
|
| 2020 |
Draganov D, Santidrian A, Minev I, Nguyen D, Zamarin D, Marincola F, Butterfield L, Minev B. Abstract 4473: Evaluation of the potential of oncolytic vaccinia virus delivered by autologous SVF to modulate innate and adaptive immunity in patients with diverse solid and hematological malignancies Immunology. DOI: 10.1158/1538-7445.Am2020-4473 |
0.409 |
|
| 2020 |
Nguyen B, Mota JM, Nandakumar S, Stopsack KH, Weg E, Rathkopf D, Morris MJ, Scher H, Kantoff PW, Gopalan A, Zamarin D, Solit DB, Schultz N, Abida W. Abstract 1308: CDK12 alterations define a distinct molecular subtype of prostate cancers with unique genomic and clinical characteristics Cancer Research. 80: 1308-1308. DOI: 10.1158/1538-7445.Am2020-1308 |
0.314 |
|
| 2019 |
Mayadev J, Zamarin D, Deng W, Lankes H, O'Cearbhaill R, Aghajanian CA, Schilder R. Anti-PD-L1 (atezolizumab) as an immune primer and concurrently with extended-field chemoradiotherapy for node-positive locally advanced cervical cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. PMID 31871115 DOI: 10.1136/Ijgc-2019-001012 |
0.306 |
|
| 2019 |
Zamarin D. Immunomodulatory Drugs Encoded by Oncolytic Viruses: Is the Whole Greater Than the Sum? Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 31586519 DOI: 10.1016/J.Ymthe.2019.09.022 |
0.302 |
|
| 2019 |
Zamarin D. Novel therapeutics: response and resistance in ovarian cancer. International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society. 29: s16-s21. PMID 31462544 DOI: 10.1136/Ijgc-2019-000456 |
0.354 |
|
| 2019 |
Liu YL, Zhou Q, Iasonos A, Emengo VN, Friedman C, Konner JA, O'Cearbhaill RE, Aghajanian C, Zamarin D. Subsequent therapies and survival after immunotherapy in recurrent ovarian cancer. Gynecologic Oncology. PMID 31421916 DOI: 10.1016/J.Ygyno.2019.08.006 |
0.346 |
|
| 2019 |
Dyer BA, Zamarin D, Eskandar RN, Mayadev JM. Role of Immunotherapy in the Management of Locally Advanced and Recurrent/Metastatic Cervical Cancer. Journal of the National Comprehensive Cancer Network : Jnccn. 17: 91-97. PMID 30659133 DOI: 10.6004/Jnccn.2018.7108 |
0.335 |
|
| 2019 |
Scott AC, Camara S, Lauer P, Synder A, Zamarin D, Walther T, Levy O, Glickman M, Kaye J, Philip M, Schietinger A. Abstract A215: Thymocyte selection-associated HMG box protein TOX is a master regulator of tumor-specific T-cell dysfunction Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A215 |
0.344 |
|
| 2019 |
Zamarin D, Odunsi K, Slomovitz B, Hubbard-Lucey VM, McCabe D, Shohara L, Schwarzenberger P, Ricciardi T, Macri M, Ryan A, Aksnes A, Kuryk L, Venhaus R. Abstract A022: Phase 1/2 study to evaluate systemic durvalumab (durva) + intraperitoneal ONCOS-102 in patients with peritoneal disease who have epithelial ovarian (OC) or metastatic colorectal cancer (CRC) Cancer Immunology Research. 7. DOI: 10.1158/2326-6074.Cricimteatiaacr18-A022 |
0.37 |
|
| 2018 |
Bykov Y, Zamarin D. Virus, Vessel, Victory: A Novel Approach to Tumor Killing. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30530816 DOI: 10.1158/1078-0432.Ccr-18-3441 |
0.479 |
|
| 2018 |
Boland JL, Zhou Q, Martin M, Callahan MK, Konner J, O'Cearbhaill RE, Friedman CF, Tew W, Makker V, Grisham RN, Hensley ML, Zecca N, Iasonos AE, Snyder A, Hyman DM, ... ... Zamarin D, et al. Early disease progression and treatment discontinuation in patients with advanced ovarian cancer receiving immune checkpoint blockade. Gynecologic Oncology. PMID 30470581 DOI: 10.1016/J.Ygyno.2018.11.025 |
0.335 |
|
| 2018 |
Liu YL, Zamarin D. Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers. Current Oncology Reports. 20: 94. PMID 30421009 DOI: 10.1007/S11912-018-0740-8 |
0.365 |
|
| 2018 |
Song M, Sandoval TA, Chae CS, Chopra S, Tan C, Rutkowski MR, Raundhal M, Chaurio RA, Payne KK, Konrad C, Bettigole SE, Shin HR, Crowley MJP, Cerliani JP, Kossenkov AV, ... ... Zamarin D, et al. IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity. Nature. PMID 30305738 DOI: 10.1038/S41586-018-0597-X |
0.339 |
|
| 2018 |
Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo K, Grisham R, O'Cearbhaill RE, Tew W, Konner J, Hensley ML, Makker V, Sabbatini PJ, Spriggs DR, et al. CLINICAL UTILITY OF PROSPECTIVE MOLECULAR CHARACTERIZATION IN ADVANCED ENDOMETRIAL CANCER. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30068706 DOI: 10.1158/1078-0432.Ccr-18-0412 |
0.328 |
|
| 2018 |
Oseledchyk A, Ricca JM, Gigoux M, Ko B, Redelman-Sidi G, Walther T, Liu C, Iyer G, Merghoub T, Wolchok JD, Zamarin D. Lysis-independent potentiation of immune checkpoint blockade by oncolytic virus. Oncotarget. 9: 28702-28716. PMID 29983890 DOI: 10.18632/Oncotarget.25614 |
0.486 |
|
| 2018 |
Zamarin D, Ricca JM, Sadekova S, Oseledchyk A, Yu Y, Blumenschein WM, Wong J, Gigoux M, Merghoub T, Wolchok JD. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. The Journal of Clinical Investigation. PMID 29504948 DOI: 10.1172/Jci98047 |
0.373 |
|
| 2018 |
Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L, Merghoub T, Wolchok JD, Zamarin D. Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29478729 DOI: 10.1016/J.Ymthe.2018.01.019 |
0.427 |
|
| 2018 |
Jelinic P, Ricca J, Van Oudenhove E, Olvera N, Merghoub T, Levine DA, Zamarin D. Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade. Journal of the National Cancer Institute. PMID 29365144 DOI: 10.1093/Jnci/Djx277 |
0.339 |
|
| 2018 |
O'Cearbhaill RE, Gnjatic S, Aghajanian C, Iasonos A, Konner JA, Losada N, Sarasohn D, Rasalan T, Tew WP, Zamarin D, Wong P, Sabbatini P. A phase I study of concomitant galinpepimut-s (GPS) in combination with nivolumab (nivo) in patients (pts) with WT1+ ovarian cancer (OC) in second or third remission. Journal of Clinical Oncology. 36: 5553-5553. DOI: 10.1200/Jco.2018.36.15_Suppl.5553 |
0.307 |
|
| 2018 |
Jelinic P, Ricca J, Van Oudenhove E, Olvera N, Merghoub T, Levine D, Zamarin D. Immune-reactive microenvironment of small cell carcinoma of the ovary, hypercalcemic type provides a rationale for evaluating immunotherapies to treat this malignancy Gynecologic Oncology. 149: 194. DOI: 10.1016/J.Ygyno.2018.04.440 |
0.316 |
|
| 2018 |
Boland J, Martin M, Zecca N, Iasonos A, Zhou Q, Aghajanian C, Sabbatini P, Cadoo K, Zamarin D. Predictors of early treatment discontinuation in ovarian cancer patients on checkpoint blockade immunotherapy Gynecologic Oncology. 149: 23-24. DOI: 10.1016/J.Ygyno.2018.04.058 |
0.306 |
|
| 2017 |
Oseledchyk A, Leitao MM, Konner J, O'Cearbhaill RE, Zamarin D, Sonoda Y, Gardner GJ, Long Roche K, Aghajanian CA, Grisham RN, Brown CL, Snyder A, Chi DS, Soslow RA, Abu-Rustum NR, et al. Adjuvant Chemotherapy in Patients with Stage I Endometrioid or Clear Cell Ovarian Cancer in the Platinum Era: A Surveillance, Epidemiology, and End Results Cohort Study, 2000-2013. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28950307 DOI: 10.1093/Annonc/Mdx525 |
0.321 |
|
| 2017 |
Jiménez-Sánchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, Ricca J, Zamarin D, Walther T, Aghajanian C, Wolchok JD, et al. Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient. Cell. 170: 927-938.e20. PMID 28841418 DOI: 10.1016/J.Cell.2017.07.025 |
0.368 |
|
| 2017 |
Dai P, Wang W, Yang N, Serna-Tamayo C, Ricca JM, Zamarin D, Shuman S, Merghoub T, Wolchok JD, Deng L. Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells. Science Immunology. 2. PMID 28763795 DOI: 10.1126/Sciimmunol.Aal1713 |
0.467 |
|
| 2017 |
Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP. Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity. Nature Communications. 8: 14340. PMID 28194010 DOI: 10.1038/Ncomms14340 |
0.589 |
|
| 2017 |
Zamarin D, Martin M, Zecca N, Iasonos A, Zhou Q, Aghajanian C, Sabbatini P. Early clinical progression in patients with gynecologic malignancies receiving immunomodulatory antibody therapy. Journal of Clinical Oncology. 35: e17087-e17087. DOI: 10.1200/Jco.2017.35.15_Suppl.E17087 |
0.351 |
|
| 2017 |
Aghajanian C, DeLair D, Grisham RN, Hensley ML, Konner JA, Makker V, O'Cearbhaill RE, Sabbatini P, Soumerai T, Snyder Charen A, Spriggs DR, Soslow RA, Tew WP, Zamarin D, Robson ME, et al. Somatic mutations in homologous recombination pathway genes in ovarian cancer. Journal of Clinical Oncology. 35: 5545-5545. DOI: 10.1200/Jco.2017.35.15_Suppl.5545 |
0.311 |
|
| 2017 |
Jiménez-Sánchez A, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, Ricca J, Zamarin D, Aghajanian C, Wolchok JD, Merghoub T, Sala E, Snyder A, et al. Abstract B09: Heterogeneous fates of metastatic lesions linked to immune escape in an ovarian cancer patient Cancer Immunology Research. 5. DOI: 10.1158/2326-6074.Tumimm16-B09 |
0.395 |
|
| 2016 |
Holmgaard RB, Zamarin D, Lesokhin A, Merghoub T, Wolchok JD. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors. Ebiomedicine. 6: 50-8. PMID 27211548 DOI: 10.1016/J.Ebiom.2016.02.024 |
0.353 |
|
| 2016 |
Zamarin D, Jazaeri AA. Leveraging immunotherapy for the treatment of gynecologic cancers in the era of precision medicine. Gynecologic Oncology. 141: 86-94. PMID 27016233 DOI: 10.1016/J.Ygyno.2015.12.030 |
0.362 |
|
| 2015 |
Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD. Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner. Cell Reports. PMID 26411680 DOI: 10.1016/J.Celrep.2015.08.077 |
0.352 |
|
| 2015 |
Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T, De Henau O, Zamarin D, Holmgaard RB, Murphy JT, Wolchok JD, Merghoub T. The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy. Advances in Cancer Research. 128: 1-68. PMID 26216629 DOI: 10.1016/Bs.Acr.2015.04.010 |
0.414 |
|
| 2015 |
Zamarin D, Pesonen S. Replication-Competent Viruses as Cancer Immunotherapeutics: Emerging Clinical Data. Human Gene Therapy. 26: 538-49. PMID 26176173 DOI: 10.1089/Hum.2015.055 |
0.463 |
|
| 2015 |
Zamarin D, Postow MA. Immune checkpoint modulation: rational design of combination strategies. Pharmacology & Therapeutics. 150: 23-32. PMID 25583297 DOI: 10.1016/J.Pharmthera.2015.01.003 |
0.389 |
|
| 2015 |
Plitt T, Zamarin D. Cancer therapy with Newcastle disease virus: rationale for new immunotherapeutic combinations Clinical Investigation. 5: 75-87. DOI: 10.4155/Cli.14.102 |
0.513 |
|
| 2014 |
Zamarin D, Wolchok JD. Potentiation of immunomodulatory antibody therapy with oncolytic viruses for treatment of cancer. Molecular Therapy Oncolytics. 1: 14004. PMID 27119094 DOI: 10.1038/Mto.2014.4 |
0.424 |
|
| 2014 |
Smith EL, Zamarin D, Lesokhin AM. Harnessing the immune system for cancer therapy. Current Opinion in Oncology. 26: 600-7. PMID 25250678 DOI: 10.1097/Cco.0000000000000128 |
0.353 |
|
| 2014 |
Zamarin D, Holmgaard RB, Subudhi SK, Park JS, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy. Science Translational Medicine. 6: 226ra32. PMID 24598590 DOI: 10.1126/Scitranslmed.3008095 |
0.561 |
|
| 2014 |
Zamarin D, Holmgaard RB, Subudhi SK, Park J, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Potentiation of immune checkpoint blockade cancer immunotherapy with oncolytic virus. Journal of Clinical Oncology. 32: 3051-3051. DOI: 10.1200/Jco.2014.32.15_Suppl.3051 |
0.617 |
|
| 2014 |
Holmgaard RB, Zamarin D, Munn DH, Merghoub T, Wolchok JD. Expression of indoleamine 2.3-dioxygenase by tumors induces local and systemic immunosuppressive effects in a murine melanoma model Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P212 |
0.353 |
|
| 2014 |
Zamarin D, Holmgaard RB, Plitt T, Allison J, Merghoub T, Wolchok JD. Potentiation of immunomodulatory antibodies with oncolytic viruses for therapy of poorly-immunogenic tumors Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P132 |
0.462 |
|
| 2013 |
Holmgaard RB, Zamarin D, Munn DH, Wolchok JD, Allison JP. Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4. The Journal of Experimental Medicine. 210: 1389-402. PMID 23752227 DOI: 10.1084/Jem.20130066 |
0.387 |
|
| 2013 |
Zamarin D, Holmgaard R, Subudhi S, Mansour M, Palese P, Merghoub T, Wolchok JD, Allison JP. Localized oncolytic virotherapy inflames distant tumors and synergizes with immune checkpoint blockade leading to systemic tumor rejection Journal For Immunotherapy of Cancer. 1. DOI: 10.1186/2051-1426-1-S1-O9 |
0.589 |
|
| 2012 |
Zamarin D, Palese P. Oncolytic Newcastle disease virus for cancer therapy: old challenges and new directions. Future Microbiology. 7: 347-67. PMID 22393889 DOI: 10.2217/Fmb.12.4 |
0.611 |
|
| 2011 |
Li P, Chen CH, Li S, Givi B, Yu Z, Zamarin D, Palese P, Fong Y, Wong RJ. Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancer. Head & Neck. 33: 1394-9. PMID 21928411 DOI: 10.1002/Hed.21609 |
0.588 |
|
| 2011 |
Davtyan H, Ghochikyan A, Cadagan R, Zamarin D, Petrushina I, Movsesyan N, Martinez-Sobrido L, Albrecht RA, García-Sastre A, Agadjanyan MG. The immunological potency and therapeutic potential of a prototype dual vaccine against influenza and Alzheimer's disease. Journal of Translational Medicine. 9: 127. PMID 21806809 DOI: 10.1186/1479-5876-9-127 |
0.37 |
|
| 2011 |
Mansour M, Palese P, Zamarin D. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. Journal of Virology. 85: 6015-23. PMID 21471241 DOI: 10.1128/Jvi.01537-10 |
0.591 |
|
| 2010 |
Silberhumer GR, Brader P, Wong J, Serganova IS, Gönen M, Gonzalez SJ, Blasberg R, Zamarin D, Fong Y. Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma. Molecular Cancer Therapeutics. 9: 2761-9. PMID 20858727 DOI: 10.1158/1535-7163.Mct-10-0090 |
0.404 |
|
| 2010 |
Dai MH, Zamarin D, Gao SP, Chou TC, Gonzalez L, Lin SF, Fong Y. Synergistic action of oncolytic herpes simplex virus and radiotherapy in pancreatic cancer cell lines British Journal of Surgery. 97: 1385-1394. PMID 20629009 DOI: 10.1002/Bjs.7124 |
0.436 |
|
| 2010 |
Song KY, Wong J, Gonzalez L, Sheng G, Zamarin D, Fong Y. Antitumor efficacy of viral therapy using genetically engineered Newcastle disease virus [NDV(F3aa)-GFP] for peritoneally disseminated gastric cancer. Journal of Molecular Medicine (Berlin, Germany). 88: 589-96. PMID 20393691 DOI: 10.1007/S00109-010-0605-6 |
0.441 |
|
| 2010 |
Wong J, Schulman A, Kelly K, Zamarin D, Palese P, Fong Y. Detection of free peritoneal cancer cells in gastric cancer using cancer-specific Newcastle disease virus. Journal of Gastrointestinal Surgery : Official Journal of the Society For Surgery of the Alimentary Tract. 14: 7-14. PMID 19902312 DOI: 10.1007/S11605-009-1071-8 |
0.541 |
|
| 2009 |
Silberhumer G, Brader P, Wong J, Zamarin D, Serganova I, Blasberg R, Palese P, Fong Y. Bioluminescence evaluation of efficacy of oncolytic treatment with Newcastle disease virus (NDV) in malignant pleural mesothelioma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e14536. PMID 27963554 DOI: 10.1200/Jco.2009.27.15_Suppl.E14536 |
0.417 |
|
| 2009 |
Chambers TM, Quinlivan M, Sturgill T, Cullinane A, Horohov DW, Zamarin D, Arkins S, García-Sastre A, Palese P. Influenza A viruses with truncated NS1 as modified live virus vaccines: pilot studies of safety and efficacy in horses. Equine Veterinary Journal. 41: 87-92. PMID 19301588 DOI: 10.2746/042516408X371937 |
0.579 |
|
| 2009 |
Zamarin D, Vigil A, Kelly K, García-Sastre A, Fong Y. Genetically engineered Newcastle disease virus for malignant melanoma therapy Gene Therapy. 16: 796-804. PMID 19242529 DOI: 10.1038/Gt.2009.14 |
0.432 |
|
| 2009 |
Zamarin D, Martínez-Sobrido L, Kelly K, Mansour M, Sheng G, Vigil A, García-Sastre A, Palese P, Fong Y. Enhancement of oncolytic properties of recombinant newcastle disease virus through antagonism of cellular innate immune responses. Molecular Therapy : the Journal of the American Society of Gene Therapy. 17: 697-706. PMID 19209145 DOI: 10.1038/Mt.2008.286 |
0.638 |
|
| 2009 |
Wong J, Schulman A, Kelly K, Zamarin D, Palese P, Fong Y. 1015 Enhancing Detection of Free Peritoneal Cancer Cells in Gastric Cancer Using Newcastle Disease Virus Gastroenterology. 136: A-883. DOI: 10.1016/S0016-5085(09)64078-6 |
0.541 |
|
| 2007 |
Conenello GM, Zamarin D, Perrone LA, Tumpey T, Palese P. A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence. Plos Pathogens. 3: 1414-21. PMID 17922571 DOI: 10.1371/Journal.Ppat.0030141 |
0.732 |
|
| 2006 |
Holmes EC, Lipman DJ, Zamarin D, Yewdell JW. Comment on "Large-scale sequence analysis of avian influenza isolates". Science (New York, N.Y.). 313: 1573; author reply 1. PMID 16973862 DOI: 10.1126/Science.1131729 |
0.35 |
|
| 2006 |
Zamarin D, Ortigoza MB, Palese P. Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice. Journal of Virology. 80: 7976-83. PMID 16873254 DOI: 10.1128/Jvi.00415-06 |
0.766 |
|
| 2006 |
Glaser L, Zamarin D, Acland HM, Spackman E, Palese P, GarcÃa-Sastre A, Tewari D. Sequence analysis and receptor specificity of the hemagglutinin of a recent influenza H2N2 virus isolated from chicken in North America. Glycoconjugate Journal. 23: 93-9. PMID 16575526 DOI: 10.1007/S10719-006-5441-0 |
0.679 |
|
| 2005 |
Zamarin D, García-Sastre A, Xiao X, Wang R, Palese P. Influenza virus PB1-F2 protein induces cell death through mitochondrial ANT3 and VDAC1. Plos Pathogens. 1: e4. PMID 16201016 DOI: 10.1371/Journal.Ppat.0010004 |
0.503 |
|
| 2005 |
Glaser L, Stevens J, Zamarin D, Wilson IA, GarcÃa-Sastre A, Tumpey TM, Basler CF, Taubenberger JK, Palese P. A single amino acid substitution in 1918 influenza virus hemagglutinin changes receptor binding specificity. Journal of Virology. 79: 11533-6. PMID 16103207 DOI: 10.1128/Jvi.79.17.11533-11536.2005 |
0.638 |
|
| 2005 |
Quinlivan M, Zamarin D, García-Sastre A, Cullinane A, Chambers T, Palese P. Attenuation of equine influenza viruses through truncations of the NS1 protein. Journal of Virology. 79: 8431-9. PMID 15956587 DOI: 10.1128/Jvi.79.13.8431-8439.2005 |
0.595 |
|
| 2005 |
Shaw ML, Cardenas WB, Zamarin D, Palese P, Basler CF. Nuclear localization of the Nipah virus W protein allows for inhibition of both virus- and toll-like receptor 3-triggered signaling pathways. Journal of Virology. 79: 6078-88. PMID 15857993 DOI: 10.1128/Jvi.79.10.6078-6088.2005 |
0.512 |
|
| Show low-probability matches. |